Estrogens, Conjugated (USP)
"Estrogens, Conjugated (USP)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.
| Descriptor ID |
D004966
|
| MeSH Number(s) |
D06.472.334.851.437.988
|
| Concept/Terms |
Estrogens, Conjugated (USP)- Estrogens, Conjugated (USP)
- Estrogens, Conjugated
- Estrogenic Hormones, Conjugated
- Conjugated Estrogenic Hormones
- Conjugated Estrogens
- Estrogenic Substances, Conjugated
- Conjugated Estrogenic Substances
Oestrofeminal- Oestrofeminal
- Oestro-Feminal
- Oestro Feminal
- Estro-Feminal
- Estro Feminal
|
Below are MeSH descriptors whose meaning is more general than "Estrogens, Conjugated (USP)".
Below are MeSH descriptors whose meaning is more specific than "Estrogens, Conjugated (USP)".
This graph shows the total number of publications written about "Estrogens, Conjugated (USP)" by people in this website by year, and whether "Estrogens, Conjugated (USP)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estrogens, Conjugated (USP)" by people in Profiles.
-
Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin. Steroids. 2008 Jan; 73(1):59-68.
-
Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS). Neurology. 2004 Mar 23; 62(6):968-70.
-
Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas. 2004 Jan 20; 47(1):47-54.
-
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003 Aug 07; 349(6):523-34.
-
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003 Jun 25; 289(24):3243-53.
-
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003 May 28; 289(20):2673-84.
-
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 03; 137(11):875-83.
-
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.
-
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26; 105(8):917-22.
-
Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause. 2002 Jan-Feb; 9(1):16-22.